Compare CLBT & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLBT | HAE |
|---|---|---|
| Founded | 1999 | 1971 |
| Country | Israel | United States |
| Employees | 1285 | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.8B |
| IPO Year | N/A | 1996 |
| Metric | CLBT | HAE |
|---|---|---|
| Price | $12.81 | $74.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $22.50 | ★ $84.13 |
| AVG Volume (30 Days) | ★ 2.0M | 984.8K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.05 |
| Revenue | N/A | ★ $910,373,000.00 |
| Revenue This Year | $21.45 | N/A |
| Revenue Next Year | $17.47 | $5.23 |
| P/E Ratio | $45.29 | ★ $37.52 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.03 | $47.32 |
| 52 Week High | $19.98 | $87.32 |
| Indicator | CLBT | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 44.41 | 62.97 |
| Support Level | $12.65 | $48.98 |
| Resistance Level | $13.95 | $86.72 |
| Average True Range (ATR) | 0.71 | 3.25 |
| MACD | -0.14 | 0.53 |
| Stochastic Oscillator | 12.03 | 55.12 |
Cellebrite DI Ltd provides AI-powered digital investigative and intelligence solutions that help public and private sector customers transform investigative workflows, make digital data more accessible and actionable, and improve the efficiency of mobile research and application security. Its solutions support law enforcement, defense, and intelligence agencies in advancing investigations, border security, counterterrorism, intelligence operations, and cyber operations. The company's software also enables enterprises and service providers to collect and review data for corporate investigations, eDiscovery, incident response, and mobile application validation. It operates in the Americas, APAC, and EMEA, with the majority of revenue from the Americas.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.